|Other Names||Nanos homolog 1, NOS-1, EC_Rep1a, NANOS1, NOS1|
|Target/Specificity||The synthetic peptide sequence used to generate the antibody AP1407b was selected from the C-term region of human NANOS1. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.|
|Format||Synthetic peptide was lyophilized with 100% acetonitrile and is supplied as a powder. Reconstitute with 0.1 ml DI water for a final concentration of 1 mg/ml.|
|Storage||Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.|
|Precautions||This product is for research use only. Not for use in diagnostic or therapeutic procedures.|
|Function||May act as a translational repressor which regulates translation of specific mRNAs by forming a complex with PUM2 that associates with the 3'-UTR of mRNA targets. Capable of interfering with the proadhesive and anti-invasive functions of E-cadherin. Up-regulates the production of MMP14 to promote tumor cell invasion.|
|Cellular Location||Cytoplasm, perinuclear region. Cytoplasm. Note=Colocalizes with SNAPIN and PUM2 in the perinuclear region of germ cells|
|Tissue Location||Testis and ovary (at protein level). Predominantly expressed in testis. Specifically expressed during germline development. In adult tissues, it is mainly expressed in spermatogonia, the stem cells of the germline. Also expressed during meiosis in spermatocytes. Not present in late, post-meiotic stage germ cells. Expressed in fetal ovaries, while it is weakly or not expressed in mature postmeiotic oocytes, suggesting that it may be expressed in premeiotic female germ cells. Expressed at high levels only in the E-cadherin deficient cell lines. Highly expressed in lung carcinomas and mostly detected in invasive tumor cells and its expression correlates with tumor aggressiveness|
email@example.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
NANOS1 may regulate translation of specific mRNAs by forming a complex with PUM2 that associates with the 3'-UTR of mRNA targets.
Strumane,K., Cancer Res. 66 (20), 10007-10015 (2006)Kurokawa,H., Dev. Growth Differ. 48 (3), 209-221 (2006)
If you have any additional inquiries please email technical services at firstname.lastname@example.org.